Rapport Therapeutics Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Rapport Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $68.29. The average 1-year stock price forecast is 172.61% higher than the current stock price, while the lowest is $50 (+99.60%) and the highest is $91 (+263.27%).

Price Target: $68.29 (+172.61%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$50	$68.29	$67	$91
Change	+99.60%	+172.61%	+167.47%	+263.27%

Analyst Ratings

The average analyst rating for Rapport Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	10	11	12	12	12	15
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	12	13	13	13	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $62 → $68	Buy	Maintains	$62 → $68	+171.46%	Oct 22, 2026
Delma Caiati Guggenheim	Guggenheim	Buy Reiterates $65 → $70	Buy	Reiterates	$65 → $70	+179.44%	Oct 21, 2026
Justin Walsh JonesTrading	JonesTrading	Buy Reiterates $50 → $82	Buy	Reiterates	$50 → $82	+227.35%	Oct 21, 2026
Jason Butler Citizens JMP	Citizens JMP	Buy Maintains $80 → $91	Buy	Maintains	$80 → $91	+263.27%	Oct 20, 2026
Tiago Fauth Raymond James	Raymond James	Buy Maintains $75 → $86	Buy	Maintains	$75 → $86	+243.31%	Oct 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

20.06M

Revenue Next Year

n/a

from 20.06M

-100.00%

from 20.06M

EPS This Year

-4.04

from -2.86

EPS Next Year

-5.09

from -4.04

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	20.06M
Operating Income	-5.85M	-36.18M	-83.06M	-125.10M	-209.15M
Net Income	-11.62M	-34.79M	-78.31M	-111.48M	-192.93M
EPS	-	-	-	-2.86	-4.04
Free Cash Flow	-	-	-	-88.09M	-190.30M
No. Analysts	-	-	-	-	16

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	21.0M
Avg	20.1M
Low	20.0M

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.50
Avg	-4.04
Low	-4.51

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-